Repligen | RGEN - Des Atouts





Des Atouts Changement Date
Agilent USD 13.07B 252M 2026-03
Align Technology USD 6.42B 103.41M 2026-06
Bio Techne USD 2.55B 27.9M 2026-03
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Bruker USD 6.05B 77.8M 2026-06
Charles River Laboratories USD 7.53B 198.16M 2026-06
Danaher USD 92.37B 8.82B 2026-06
Dentsply International USD 5.2B 25M 2026-06
General Electric Aerospace USD 127.67B 773M 2026-06
Henry Schein USD 11.38B 77M 2026-06
Illumina USD 6.65B 91M 2026-06
IQVIA Holdings USD 29.88B 206M 2026-06
Mettler Toledo International USD 3.67B 2.03M 2026-06
Myriad Genetics USD 638.9M 34.8M 2026-06
OraSure Technologies USD 360.55M 18.62M 2026-06
Pacific Biosciences Of California USD 751.85M 30.51M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Repligen USD 2.95B 19.41M 2026-06
Revvity USD 12.05B 49.24M 2026-06
Standard Biotools USD 639.11M 71.36M 2026-03
Thermo Fisher Scientific USD 113.17B 107M 2026-06
Waters USD 24.75B 220M 2026-06
West Pharmaceutical Services USD 4.08B 33.4M 2026-06